国庆中秋假期将至，为方便市民假期就医，长江日报独家整理了武汉市40余家医疗机构 假期门诊安排（不完全收录）。这份"就医指南"请收好，助您健康安心过双节！ 华中科技大学同济医学院附属同济医院： 10月1日、10月6日门诊停诊，急诊、发热门诊24小时应诊。 10月2日—10月5日、10月7日—10月8日专家门诊、普通门诊正常接诊。 健康管理中心10月1日—10月6日停诊，10月7日上午、10月8日上午正常接诊。 生殖医学中心节假日期间正常接诊。 "同济云医"线上门诊、自助开单等业务正常接诊。 汉口院区、光谷院区、中法新城院区、同济军山医院门诊安排保持一致。 华中科技大学同济医学院附属协和医院： 10月1日—10月8日，门急诊照常。请参照平时周一至周日专门门诊排班，实时挂号信息 可查看武汉协和医院官方微信（whuh1866）智慧医院—挂号服务栏目。 武汉大学人民医院（湖北省人民医院）： 国庆假期期间，主院区（首义院区）、东院区（光谷院区）、洪山院区"一院三区"普通 门诊、急诊、机能室（含各学科机能室）、专家门诊照常。服务电话：027-88999120。 门诊具体排班可通过微信公众号"湖北省人民医院"、微信小程序"武 ...

Company Overview - He Eye Hospital Group, established on October 15, 2009, is located in Shenyang, Liaoning Province, and was listed on March 22, 2022 [1] - The company primarily provides specialized ophthalmic diagnosis and treatment services, with revenue composition as follows: Vision services 30.24%, Refractive surgery correction services 24.16%, Non-surgical treatment 20.02%, Cataract diagnosis and treatment services 13.68%, Vitreoretinal diagnosis and treatment services 8.09%, Other ophthalmic diagnosis and treatment services 3.20%, Other business income 0.61% [1] Financial Performance - As of June 30, 2025, He Eye Hospital reported operating revenue of 560 million yuan, a year-on-year decrease of 4.22%, while net profit attributable to shareholders was 44.32 million yuan, reflecting a year-on-year increase of 84.19% [2] - The company has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] Stock Performance - As of September 30, the stock price of He Eye Hospital increased by 2.14% to 21.03 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Year-to-date, the stock price has risen by 5.29%, with a 1.69% increase over the last five trading days, but a decline of 3.93% over the last 20 days and 3.53% over the last 60 days [1] - The number of shareholders increased by 15.03% to 10,800, while the average circulating shares per person decreased by 13.07% to 7,684 shares [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7947 million shares, a decrease of 1.7584 million shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

妇产科医生说,对于许多准父母来说,婴儿的健康是一个持续的问题,所以越来越多的孕妇开始她们在怀孕 期间应该做什么检查。怀孕期间做过多少次四维彩色多普勒超声?针对这些问题,让我们看看深圳永福医 院妇产科医生的介绍。 孕14周左右,孕妇可以做四维彩超检查,检查胎儿的四肢发育情况和一邓工。在这个阶段,四维彩超检查不 会很好地显示胎儿的内脏器官,面部显示的效果也会比较差。 以上问题就是我们对于孕期做几次四维彩超的介绍,对于一个孕妇们而言,应该可以在其孕早、中、晚这 三个发展阶段各进行一次四维彩超检查,对自己的健康教育负责,同时也为自己宝宝的健康管理负责。 深圳永福医院作为深圳市卫计委批准建设的一家集医疗、教学、科研、保健、康复、急救、社区服务于 一体的现代化综合医院,规划建筑面积4万余平方米,床位600张,现已列入深圳市政府卫生规划重点建设项 目,按照三级综合医院标准建设,是深圳市医疗保险、生育保险、健康体检单位。 2、孕22周左右 在此期间做四维彩色多普勒超声可以清楚地了解胎儿面部发育,筛查无脑儿、重度脑膨出和严重脊柱裂 等胎儿发育异常。 3、孕14周左右 1、孕28周左右 孕妇在这段时间做四维彩超检查就可以更加清晰 ...

Core Insights - The event held on September 27 in Guangzhou focused on the high-quality development of public hospitals, emphasizing the role of digital intelligence in driving this progress [1] Group 1: Challenges and Solutions in Digital Transformation - Hospital administrators highlighted the "bottleneck" issues in digital transformation, primarily related to resistance in process restructuring driven by data and insufficient organizational coordination [4] - Solutions proposed include top-level design focusing on enhancing medical quality, patient safety, and operational efficiency, as well as adopting a "small steps, quick wins" strategy to address pain points in patient care [4] - The need for a tiered approach to talent development was emphasized, aiming to enhance the leadership skills of mid-level managers and the digital literacy of frontline medical staff [4] Group 2: Policy Alignment and Health Management - The shift from a disease-centered to a health-centered approach in hospital development was discussed, alongside the need to address three major conflicts: traditional service models versus efficiency, diverse patient needs versus limited resources, and single treatment supply versus proactive health demands [4] - Digital technologies are seen as essential for supporting comprehensive health management systems for children and integrated care models in maternal and child health [4] Group 3: Practical Applications and Innovations - Beijing University Third Hospital has developed 153 application systems covering patient services, clinical applications, and comprehensive management, significantly improving diagnostic accuracy and patient experience [5] - The hospital has implemented AI technologies for rare disease diagnosis and quality control of medical records, while also reducing energy costs through monitoring systems [5] - The Capital Institute of Pediatrics has introduced child-friendly services and AI early screening models for various pediatric conditions, aiming to extend healthcare services into communities and families [5] Group 4: Collaborative Efforts and Future Directions - The importance of steady and practical advancement in digital transformation was emphasized, with a call for collaboration among stakeholders to integrate digital technologies into all aspects of healthcare services [6]

Core Insights - The event held in Guangzhou focused on the high-quality development of public hospitals, with various stakeholders sharing innovative practices and experiences to contribute to this goal [1] Group 1: Cultural and Organizational Development - Jiangxi Nanchang University Affiliated Stomatological Hospital emphasized the importance of integrating "truth power" and "personality power" in cultural construction, aiming for a vision that includes patient satisfaction, employee happiness, and student success [2] - Guangzhou Medical University Affiliated Second Hospital shared its experience in optimizing organizational structure by establishing party branches within departments, ensuring that party work and business development are closely aligned [3] Group 2: Specialized Capacity Building - Jiangsu Jiangnan University Affiliated Hospital highlighted the significance of specialized capacity building in enhancing overall competitiveness and optimizing medical resource allocation, focusing on key clinical specialties to drive collaborative development [4] - Jiangxi Jiujiang First People's Hospital discussed the importance of differentiated development in specialized construction, particularly in nuclear medicine, to improve diagnostic and treatment capabilities in line with regional development plans [4]

Core Viewpoint - Innovation Medical's stock has shown significant volatility, with a year-to-date increase of 157.54%, but recent declines in the short term indicate potential market fluctuations [1][2]. Group 1: Stock Performance - On September 29, Innovation Medical's stock rose by 2.09%, reaching 20.50 CNY per share, with a trading volume of 4.36 billion CNY and a turnover rate of 5.17%, resulting in a total market capitalization of 90.46 billion CNY [1]. - Year-to-date, the stock has increased by 157.54%, but it has decreased by 4.78% over the last five trading days and 18.62% over the last 20 days, while showing a 35.14% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" 18 times this year, with the most recent appearance on September 5, where it recorded a net buy of -1.21 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Innovation Medical reported a revenue of 402 million CNY, reflecting a year-on-year decrease of 1.60%, while the net profit attributable to the parent company was -11.36 million CNY, showing a year-on-year increase of 29.12% [2]. - Since its A-share listing, the company has distributed a total of 55.87 million CNY in dividends, with no dividends paid in the last three years [2]. Group 3: Shareholder Information - As of June 30, the number of shareholders for Innovation Medical was 82,000, an increase of 20.38% from the previous period, with an average of 5,074 circulating shares per person, a decrease of 16.93% [2].

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.2% from September 22 to September 26, underperforming compared to the Wind All A index (0.25%) and the CSI 300 index (1.07%) [3][8] - The flu season is becoming active, with monitoring data indicating a slow upward trend in respiratory infectious diseases, particularly in southern provinces [3][12] - The upcoming ESMO conference from October 17 to 21 in Berlin will feature significant research contributions from Chinese scholars, with 23 studies included in the Late-Breaking Abstracts [3][12] Market Weekly Review - The pharmaceutical and biotechnology sector declined by 2.2%, with only the other biological products sector showing a slight increase of 0.05%. The raw materials sector saw a significant drop of 8.22% [8][9] - Notable stock performances included Sunflower (57.9% increase), Aopumai (23.9% increase), and Xinlitai (15.8% increase), while Borui Pharmaceutical (-38.4%) and Zhongsheng Pharmaceutical (-14%) faced significant declines [11][12] Industry News and Key Company Announcements - The National Healthcare Security Administration launched a "100-day action" to address prominent issues in medical insurance fund management, effective until December 31, 2025 [12][13] - Pfizer announced its acquisition of Metsera for approximately $4.9 billion, focusing on developing next-generation obesity and cardiometabolic disease drugs [16][17] - The ESMO conference has highlighted 23 groundbreaking studies from Chinese researchers, marking a significant achievement for the industry [16][17]

Core Insights - The successful treatment of a severe liver failure patient at Qilu Hospital Dezhou demonstrates the effectiveness of artificial liver technology and multidisciplinary collaboration in critical care [1][2] Group 1: Patient Case Overview - A 68-year-old male patient, Mr. Zhang, was admitted with severe liver conditions including hepatitis C, hepatitis B, cirrhosis, liver cancer, and acute liver failure, indicating a critical health status [1] - The medical team, led by Director Wang Hongbin, formed a specialized treatment team to address the patient's complex condition through a comprehensive approach [1] Group 2: Treatment Approach - The treatment involved a multidisciplinary team (MDT) that included specialists from various departments, providing tailored treatment recommendations based on the patient's overall condition [1] - The team implemented a personalized and detailed treatment plan focusing on liver protection, antiviral therapy, and nutritional support [1] Group 3: Use of Artificial Liver Technology - Due to the rapid deterioration of the patient's liver function, conventional drug treatments were insufficient, leading to the decision to utilize the artificial liver support system [2] - The artificial liver treatment, combined with multidisciplinary care, significantly improved the patient's coagulation function and stabilized vital signs, allowing for further treatment opportunities [2] Group 4: Hospital's Commitment - The successful case highlights Qilu Hospital Dezhou's advanced capabilities in treating severe liver failure and its ongoing commitment to enhancing specialized diagnostic and treatment capabilities [2]

Core Insights - The article highlights a significant change in the accessibility of medical services in Beijing, particularly for patients from outside the city, with a notable decrease in the number of external patients seeking treatment in major hospitals [1][5][6]. Group 1: Patient Access and Trends - Patients from outside Beijing have experienced a reduction in the need to travel to the city for medical care, with many able to secure same-day appointments at top hospitals [2][4]. - The proportion of external patients in Beijing's hospitals has decreased from a peak of 28.9% in 2019 to 30.15% in 2023, indicating a shift in patient demographics [6][7]. - The establishment of regional medical centers and local healthcare improvements has contributed to this trend, allowing patients to receive care closer to home [9][10][12]. Group 2: Healthcare Supply Expansion - Over the past decade, Beijing has expanded its healthcare supply significantly, adding 73 hospitals and increasing bed capacity by 33,000, resulting in a bed-to-population ratio of 7.09 per 1,000 people [18]. - Despite the increase in healthcare facilities, the bed occupancy rate has not returned to pre-pandemic levels, indicating a more balanced supply-demand dynamic [28][29]. - New hospital branches and expansions, such as the Beijing University First Hospital's Daxing branch, are expected to further alleviate patient congestion in central hospitals [23][24].